drugset / Trial / NCT05762471
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
Phase 1/2
Completed
142 enrolled
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV) and Type 2 Diabetes Mellitus on Metformin (T2DM) This study includes 5 planned cohorts. Participants will receive multiple-ascending doses of GSBR-1290 or Placebo from Day 1 to Day 84
Timeline
- Start
- 2023-01-09
- Primary completion
- 2024-04-11
- Completion
- 2024-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aleniglipron | Small molecule | — | — |